Diverse group walking towards a bright future with PrEP and HIV prevention.

PrEP: Your Comprehensive Guide to HIV Prevention

Elliot Brynn monogram
Elliot Brynn in Health & Wellness October 2026 • 4 min read.

"Discover how pre-exposure prophylaxis (PrEP) is revolutionizing HIV prevention, offering new hope and opportunities for at-risk individuals."


For nearly four decades, the HIV/AIDS pandemic has cast a long shadow across the globe. But with the advent of highly effective antiretroviral treatments, the tide is turning. These treatments have not only saved millions of lives but have also virtually eliminated the risk of HIV transmission for those who adhere to their regimens and achieve undetectable viral loads.

Now, there's another powerful tool in the fight against HIV: pre-exposure prophylaxis, or PrEP. Compelling evidence shows that PrEP, when taken consistently, can prevent millions of new HIV infections. This realization has led to ambitious global goals, including the United Nations' (UN) Sustainable Development Goal of ending AIDS as a public health threat by 2030.

To reach this ambitious goal, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has launched a 'Fast-Track' approach, emphasizing a rapid expansion of HIV prevention services. A key target is to have three million people on PrEP by 2020, setting the stage for a new era in HIV prevention.

AI Search Multiple angles on this topic

PrEP’s Preventive Impact

PrEP is prescription medicine, available as pills or shots, for adults and adolescents without HIV who may be exposed through sex or injection drug use. HIV.gov reports that PrEP can reduce the risk of getting HIV by as much as 99%, while the CDC describes it as a prevention option that can also help during conception, pregnancy, and breastfeeding. The CDC also presents PrEP as part of a broader prevention plan that may include condom use and STI screening.

Medication-Based Prevention

Pre-exposure prophylaxis is a preventive approach used before exposure to a disease-causing agent. The listed source explains that PrEP can involve drug treatment, also called chemoprophylaxis, rather than vaccination. This broad definition identifies the method’s purpose but does not provide source-based details about its limitations or comparative effectiveness.

An Evolving Prevention Field

The historical development of HIV PrEP reflects a broader evolution in preventive medicine. Its story can be understood as the gradual development of approaches intended to reduce HIV exposure before infection occurs. Specific milestones and dates are not established by the sources provided here.

What is PrEP and How Does it Work?

Diverse group walking towards a bright future with PrEP and HIV prevention.

PrEP involves taking antiretroviral medications daily to prevent HIV infection in people who are HIV-negative but at risk. These medications work by blocking HIV from establishing itself in the body if exposure occurs.

However, getting PrEP to the people who need it most has proven challenging. As of now, PrEP services are only available in a limited number of settings, creating disparities in access and hindering the overall impact of this prevention strategy.

  • Setting PrEP Targets: Many countries are establishing national targets for PrEP implementation to guide their efforts.
  • PrEP Policies: An increasing number of countries are developing national PrEP policies to support the widespread use of PrEP.
  • Integrating PrEP: Integrating PrEP into existing sexual health services can maximize resources and streamline care.
  • Community Involvement: Community-based approaches are crucial for reaching key populations and addressing local needs.
AI Search Multiple angles on this topic

Continuing Evidence Development

Research on HIV PrEP continues to evaluate how preventive medication can be used effectively in different circumstances. Current reviews may examine delivery methods, adherence, and access, but the sources provided do not identify particular studies or findings. Any conclusions about the newest evidence should therefore be checked against current clinical research and guidance.

Limits in Real-World Use

PrEP’s effectiveness in practice can depend on whether people can obtain it, use it as prescribed, and receive appropriate clinical support. Prevention strategies may also face barriers involving access, acceptability, or continuity of care. The sources provided do not document specific failures, rates, or counterarguments, so those issues should be described cautiously.

PrEP Among Prevention Options

PrEP is one possible approach within the wider field of HIV prevention. A meaningful comparison with condoms, testing, treatment as prevention, or other methods would require evidence about each option’s effectiveness, use, and limitations. The supplied sources do not provide enough comparative data to rank these strategies.

There is increasing urgency, which can be navigated with PrEP implementation and what steps need to be taken by providers. These insights come from pioneers in PrEP implementation around the world.

The Road Ahead: Expanding PrEP Access Globally

With more countries embracing PrEP implementation and PrEP service provision on the rise, it's crucial to foster open discussions about the opportunities and challenges that service providers face. By sharing knowledge and inspiring innovation, we can accelerate the expansion of PrEP around the world. Together, we can reach the global PrEP-coverage target and bring an end to the HIV/AIDS epidemic.

AI Search Multiple angles on this topic

A Comprehensive Prevention Strategy

PrEP is best considered as one component of a comprehensive HIV prevention plan. A balanced approach may involve discussing prescribed use, condom use, STI screening, and other risk-reduction measures with a health care professional. The available sources support this integrated framing but do not provide independent expert commentary.

Expanding Prevention Choices

The availability of both pills and shots suggests that HIV prevention may continue to develop around multiple delivery options. Future progress could involve making preventive care easier to access and sustain for people with different needs. The sources provided do not establish specific future products, timelines, or research milestones.

Access and Prevention Infrastructure

PrEP operates within health systems that must support prescription, follow-up care, prevention counseling, and testing. Its broader impact may depend not only on the medicine itself but also on whether people can reach and use relevant services. The supplied sources do not specify particular disparities, policy barriers, or health-system outcomes.

Personalized Prevention

People may consider PrEP when they face possible HIV exposure through sex or injection drug use. The CDC also identifies circumstances involving conception, pregnancy, and breastfeeding in which PrEP may help prevent HIV exposure to both the individual and their baby. Decisions about using PrEP are personal and should be discussed with a health care professional.

What the group comparison shows

The lower infection rate in the immediate group is a comparison with a deferred-start group, not a comparison with no prevention services: participants in the deferred group also received post-exposure prophylaxis prescriptions. The result therefore describes the difference between these groups under the trial conditions.[1]

In the immediate group, participants were told that maximum protection would be reached only after drug concentrations reached steady state. This makes clear that the result does not mean protection was immediate upon starting medication.[1]

How trial results compare across settings

HPTN 084’s pooled incidence was lower than the rates described for other recent prevention trials in sub-Saharan Africa; the cited account says this supports the effectiveness of both study agents for PrEP in women.[2]

The review reports that the only trial of on-demand PrEP found the same rate reduction as the only comparable daily-use trial. Both trials enrolled many men who have sex with men and had high adherence, which narrows how broadly that comparison can be applied.[3]

The FDA approval of injectable lenacapavir adds a six-monthly delivery option to the prevention landscape, based on two randomized controlled trials. This establishes the approval and its stated basis, rather than a direct comparison with the oral regimens described in the other facts.[4]

What PrEP evidence still needs to clarify

  • How does breakthrough-infection risk differ between cisgender women and cisgender men or transgender women who have sex with men, and what might that mean for subsequent response to commonly used dolutegravir-based treatment?[2]

Sources

  1. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial (pmc.ncbi.nlm.nih.gov)
  2. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial (pmc.ncbi.nlm.nih.gov)
  3. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations (pmc.ncbi.nlm.nih.gov)
  4. Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 (www.cdc.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is PrEP, and how does it protect against HIV?

PrEP, or pre-exposure prophylaxis, involves taking antiretroviral medications daily. These medications prevent HIV from establishing itself in the body if exposure occurs. By consistently taking PrEP, individuals at risk of HIV can significantly reduce their chances of infection, offering a powerful tool in HIV prevention. Note that PrEP is most effective when taken as prescribed and should be part of a comprehensive prevention strategy, including regular testing and safe sexual practices.

2

What are some of the challenges in getting PrEP to the people who need it most, and what strategies are being implemented to address these issues?

One significant challenge is the limited availability of PrEP services, which creates disparities in access. To combat this, many countries are establishing national targets for PrEP implementation and developing national PrEP policies. Integrating PrEP into existing sexual health services helps maximize resources and streamline care. Additionally, community-based approaches are crucial for reaching key populations and addressing local needs, ensuring that PrEP is accessible to those who would benefit most from it. Further efforts are needed to address cost, awareness, and stigma associated with PrEP.

3

What is the 'Fast-Track' approach by UNAIDS, and how does PrEP fit into the plan to end AIDS as a public health threat by 2030?

The Joint United Nations Programme on HIV/AIDS (UNAIDS) launched a 'Fast-Track' approach to rapidly expand HIV prevention services. A key target within this approach was to have three million people on PrEP by 2020. PrEP plays a vital role in this plan by preventing new HIV infections among at-risk individuals, thereby contributing to the Sustainable Development Goal of ending AIDS as a public health threat. The 'Fast-Track' approach also emphasizes increased testing, treatment, and viral suppression, working synergistically with PrEP to achieve epidemic control.

4

How effective is PrEP in preventing HIV transmission, and what does consistent use mean in maximizing its benefits?

Compelling evidence shows that PrEP, when taken consistently, can prevent millions of new HIV infections. Consistent use means adhering to the daily regimen of antiretroviral medications as prescribed by a healthcare provider. When taken correctly, PrEP is highly effective at preventing HIV infection. However, its effectiveness diminishes if it is not taken consistently. Consistent use ensures that there is a sufficient level of medication in the body to block HIV if exposure occurs. In addition to consistent PrEP use, regular HIV testing and safer sex practices are recommended for comprehensive prevention.

5

Besides the use of PrEP, what other HIV prevention strategies are crucial in the fight against HIV/AIDS?

While PrEP is a powerful tool, a comprehensive approach to HIV prevention also includes consistent condom use, regular HIV testing, prompt treatment for those who are HIV-positive to achieve and maintain an undetectable viral load (which prevents transmission), and access to clean needles for people who inject drugs. Additionally, addressing social determinants of health, such as poverty, stigma, and discrimination, is essential for creating an environment where HIV prevention efforts can be most effective. Integrating these strategies with PrEP offers the best chance of ending the HIV/AIDS epidemic.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.